REGULATORY
Japan Finalizes Deal for Pfizer’s COVID-19 Pills, Eyes Approval by Mid-February
Japan has reached a definitive pact with Pfizer to receive the company’s oral COVID-19 treatment for 2 million people this year, Health Minister Shigeyuki Goto said on February 1. The government is aiming for the drug’s approval by the middle…
To read the full story
Related Article
- Pfizer’s Paxlovid Can Now Be Used Across Japan on In-Hospital Dispensing
March 1, 2022
- Pfizer’s Paxlovid Contraindicated with Many Medicines, Requires Careful Use
February 14, 2022
- Japan Approves Pfizer’s Paxlovid, Second Oral COVID-19 Pill
February 10, 2022
- Pfizer’s COVID-19 Pill Up for PAFSC Review on Feb. 10
February 4, 2022
- Pfizer Files Oral COVID-19 Pill in Japan
January 14, 2022
- Pfizer Agrees to Supply Oral COVID-19 Drugs for 2 Million People in Japan
December 20, 2021
REGULATORY
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
- Takeda to Shift Immunoglobulin Production to 10% Formulation
June 29, 2026
- Japan’s Immunoglobulin Self-Sufficiency Rate Falls Below 60%
June 29, 2026
- MOF Panel Renews Push for Full-Scale Off-Year Revision in FY2027
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





